$EXEL News

Exelixis Rises with Earnings on Tap

Exelixis (EXEL) Stock May Be A Bargain Despite Its 223% Run

Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

Exelixis (NASDAQ:EXEL): A Quality Stock With Durable Returns on Capital

RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51

RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45

Is Exelixis (EXEL) Fully Valued As Its Cabozantinib Patent Window Comes Into Focus?

Exelixis (EXEL) Stock May Be Undervalued As Earnings Stay In Focus

Exelixis (NASDAQ:EXEL) Flashes Strong Technicals and Tight Breakout Setup

Exelixis Shares Rising on CABOMETYX Revenue

Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer

Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?

Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade)

Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises

Exelixis: The FDA Delay Costs Less Than The Market Thinks